Platelet Activation Induced by a Human Neuroblastoma Tumor Cell Line Is Reduced by Prior Administration of Ticlopidine

Summary

Ticlopidine (250 mg twice daily) was administered to human volunteers for seven days and the response of their heparinized platelet-rich plasma to SKNMC (ADP-dependent) human neuroblastoma cells was examined. The first wave of platelet aggregation, characteristic of ADP-dependent human tumor cell lines, was completely abolished but was replaced by a lag period prior to the onset of aggregation. In the Baumgartner perfusion apparatus there was a marked inhibition in the thrombus generated by the presence of SKNMC cells with a concomitant increase in the percentage of surface coverage. These results suggest that the administration of ticlopidine could be useful to prevent some of the steps of metastatic dissemination in which activated platelets may play a role.

Keywords

Platelet activation - Human neuroblastoma - Ticlopidine Summary

• References

• 1 Gasic GJ, Gasic TB, Steward CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 1968; 61: 46-52
• 2 Warren BA. Platelet-tumor cell interactions. Morphological studies In: Platelets: A multidisciplinary approach De Gaetano G, Garattini S. (eds Raven Press; New York: 1978: 427-442
• 3 Gordon S, Witul M, Cohen M, Sciandra J, Williams P, Gastpar M, Murphy GP, Ambrus JL. Studies in platelet aggregation inhibitors in vivo. Effects of pentoxifyllin on spontaneous tumor metastasis. J Med 1979; 10: 435-441
• 4 Lerner WA, Pearlstein E, Ambrogio C, Karpatkin S. A new mechanism for tumor-induced platelet aggregation. Comparison with mechanisms shared by other tumors with possible pharmacologic strategy toward prevention of metastasis. Int J Cancer 1983; 31: 463-469
• 5 Holme R, Oftebro R, Hovig T. In vitro interaction between cultured cells and human blood platelets. Thromb Haemostas 1978; 40: 89-102
• 6 Pearlstein E, Cooper LB, Karpatkin S. Extraction and characterization of a platelet-aggregating material from SV40-transformed mouse 3T3 fibroblasts. J Lab Clin Med 1978; 93: 332-344
• 7 Bastida E, Ordinas A, Jamieson GA. Differing platelet aggregating effects by two tumor cell lines: Absence of role for platelet-derived ADP. Am J Hematol 1981; 11: 367-378
• 8 Mohanty D, Hilgard P. A new platelet aggregating material (PAM) in an experimentally induced rat fibrosarcoma. Thromb Haemostas 1984; 51: 192-195
• 9 Schmaier AH, Day HJ. A classification of disorders of hemostasis and thrombosis in patients with malignancy. In:Interaction of platelets with tumor cells Jamieson GA. (ed) Alan Liss; New York: 1982: 1-20
• 10 Rickies FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau,s syndrome revisited. Blood 1983; 62: 14-31
• 11 Gasic GJ, Gasic TB, Galanti N, Johnson T, Murphy S. Platelet-tumor cell interactions in mice. The role of platelets in the spread of malignant disease Int J Cancer 1973; 704-711
• 12 Honn KV, Ciccone B, Skoff A. Prostacyclin: a potent antimetastatic agent. Science 1981; 212: 1270-1272
• 13 Honn KV, Onoda JM, Diglio CA, Carufel MM, Taylor JD, Sloane BF. Inhibition of tumor cell-platelet interactions and tumor metastasis by the calcium channel blocker nimodipine. Clin Expl Metastasis 1984; 2: 61-72
• 14 Hilgard P, Heller H, Schmidt GC. The influence of platelet aggregation inhibitors on metastasis formation in mice (3LL). Z Krebsforsch 1976; 86: 243-250
• 15 Evans PM, Cowie FP. A species difference in platelet aggregation induced by tumor cells. Cell Biol Int Rep 1983; 7: 771-779
• 16 Marcum JM, McGill M, Bastida E, Ordinas A, Jamieson GA. Interaction of platelets, tumor cells and vascular endothelium. J Lab Clin Med 1980; 96: 1046-1052
• 17 Bastida E, Ordinas A, Escolar G, Jamieson GA. Tissue factor in microvesicles shed from U87MG human glioblastoma cells induces coagulation, platelet aggregation and thrombogenesis. Blood 1984; 64: 177-183
• 18 Bastida E, Ordinas A, Giardina SL, Jamieson GA. Differentiation of platelet aggregating effects of human tumor cell lines based on inhibition studies with apyrase, hirudin and phospholipase. Cancer Res 1982; 42: 4348-4352
• 19 Ashida SI, Abico Y. Mode of action of ticlopidine in inhibition of platelet aggregation in the rat. Thromb Haemostas 1979; 41: 436-449
• 20 Lips JP M, Sixma JJ, Schiphorst ME. The effects of ticlopidine administration to humans on the binding of adenosine diphosphate to blood platelets. Thromb Res 1980; 17: 19-27
• 21 Dunn F, Soria CJ, Rhomaidis A, Lee N, Tobelem G, Caen JP. Effect de l’administration de ticlopidine sur la fixation de fibrinogene au niveau des plaquettes. Nouvelle Revue Fran Hematol 1983; 25: 132-133
• 22 Di Minno G, Cerbone AM, Mattioli PL, Turco S, Iovine C, Mancini M. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest 1985; 75: 328-338
• 23 Lalau-Keraly C, Delautier D, Delabassée D, Chignard M, Benveniste J. Inhibition by ticlopidine of PAF-acether-induced in vitro aggregation of rabbit and human platelets. Thromb Res 1984; 34: 463-471
• 24 Pumphrey CW, Fuster V, Dewanjee MK, Murphy KP, Vlietstra RE, Kaye MP. A new in vivo model of arterial thrombosis. The effect of administration of ticlopidine and verapamil in dogs. Thromb Res 1982; 28: 663-665
• 25 Driot F, Maffrand JP, Vallée E. Platelet-subendothelium interaction: Effects of ticlopidine. Thromb Haemostas 1983 50. 379 (Abstr)
• 26 Cattaneo M, Wincour PD, Somers DA, Groves HM, Kinlough-Rathbone RL, Packham MA, Mustard JF. Effect of ticlopidine on platelet aggregation, adherence to damaged vessels, thrombus formation and platelet survival. Thromb Res 1985; 37: 20-43
• 27 Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvas Res 1973; 5: 167-178
• 28 Escolar G, Bastida E, Castillo R, Ordinas A. Development of a computer analysis program to evaluate the interactions of platelets with subendothelium. Haemostasis 1986; 16: 8-14
• 29 Bastida E, Escolar G, Ordinas A, Giardina SL, Jamison GA. Effects of divalent cations on the interaction of platelets with tumor cells: Aggregation and perfusion studies with two homologous human systems. J Lab Clin Med 1985; 106: 68-74
• 30 Tanaka J, Kohaga S, Ogawa H, Ishidasa M, Tanaka K. Effect of ticlopidine in blood borne metastasis. In: Metastasis Clinical and Experimental Aspects, vol 4, pp 147-152 Hellmann K, Hilgent P, Eccles S. (eds). Martinus Nijhoff; La Hague: 1980
• 31 Piovella F, Ricetti MM, Samaden A, Semino G, Almasio P, Custodi P, Ascari E. Ticlopidine reduces intra-platelet fibronectin levels: Another mechanism of action for this drug. Thromb Haemostas 1985; 54: 64 (Abstr)